Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
16.52
+1.35 (8.90%)
Nov 9, 2026, 3:43 PM EST - Market open
Greenwich LifeSciences Earnings Call Transcripts
Fiscal Year 2025
-
A phase III trial is underway for a HER2-targeted breast cancer vaccine, showing strong immune responses and safety similar to phase II. The company is expanding enrollment, maintains a low burn rate, and sees significant market and cost-saving potential, with future strategic partnerships possible.
Fiscal Year 2024
-
A phase III trial for a breast cancer recurrence vaccine is enrolling globally, with strong phase II data, a large commercial opportunity, and upcoming milestones including interim analysis and expanded trial arms. Pharma partnership interest is high as the company advances toward commercialization.